journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/28097373/vaccination-of-allogeneic-hematopoietic-stem-cell-transplant-recipients-what-should-be-considered
#1
LETTER
Inken Hilgendorf, Hildegard Greinix, Jörg Halter, Anita Lawitschka, Daniel Wolff
No abstract text is available yet for this article.
January 17, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28091736/salvage-therapy-for-acute-chemorefractory-leukemia-by-allogeneic-stem-cell-transplantation-the-korean-experience
#2
Shin Hye Yoo, Youngil Koh, Dae-Young Kim, Jung-Hee Lee, Je-Hwan Lee, Kyoo-Hyung Lee, Sung-Soo Yoon, Seonyang Park, Sung-Kyu Park, Dae-Sik Hong, Hyeon Gyu Yi, Chul-Soo Kim, Ji Eun Jang, June-Won Cheong, Joonho Moon, Yoo Hong Min, Sang Kyun Sohn, Inho Kim
Little is known about the characteristics that make patients with acute leukemia suitable for undergoing salvage therapy by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we analyzed the clinical outcomes of 223 patients with acute leukemia who underwent allo-HSCT while not in complete remission (CR). The primary end points were overall survival (OS) and CR rate. CR was achieved in 79.8% of patients after allo-HSCT. Acute graft-versus-host disease (GVHD) was significantly associated with CR (P = 0...
January 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28091735/comprehensive-assessment-of-peripheral-blood-tcr%C3%AE-repertoire-in-infectious-mononucleosis-and-chronic-active-ebv-infection-patients
#3
Shenglin Liu, Qian Zhang, Dongli Huang, Wenli Zhang, Fengluan Zhong, Jia Feng, Xueru Chen, Qingxiang Meng, Xiaofan Chen, Wei Zhang, Hongyu Zhang
Epstein-Barr virus (EBV) primary infection is usually asymptomatic, but it sometimes progresses to infectious mononucleosis (IM). Occasionally, some people develop chronic active EBV infection (CAEBV) with underlying immunodeficiency, which belongs to a continuous spectrum of EBV-associated lymphoproliferative disorders (EBV(+) LPD) with heterogeneous clinical presentations and high mortality. It has been well established that T cell-mediated immune response plays a critical role in the disease evolution of EBV infection...
January 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28084534/outcome-of-anti-thymocyte-immunoglobulin-plus-cyclosporine-a-for-severe-aplastic-anaemia-with-chronic-hepatitis-b-virus-infection
#4
Miao Chen, Junling Zhuang, Daobin Zhou, Ying Xu, Yongqiang Zhao, Shujie Wang, Wei Zhang, Minghui Duan, Tienan Zhu, Jian Li, Huacong Cai, Xinxin Cao, Bing Han
The influence of chronic hepatitis B virus (HBV) infection on the efficacy of intensive immunosuppressive treatment (IST) of severe aplastic anaemia (SAA) patients remains unclear. Previous reports on this topic have been mostly case reports or have had a relatively short follow-up. Eight SAA patients carrying chronic HBV infection and 24 matched patients without HBV at a ratio of 1:3 were included in this retrospective analysis. The patients were treated with anti-thymocyte globulin (ATG) and cyclosporine A...
January 13, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28074255/bortezomib-containing-regimens-bcr-for-the-treatment-of-non-transplant-eligible-multiple-myeloma
#5
Victor H Jimenez-Zepeda, Peter Duggan, Paola Neri, Jason Tay, Nizar J Bahlis
In multiple myeloma (MM) patients ineligible for transplant, the selection of up-front therapy needs to balance efficacy and toxicity. Recently, regimens with bortezomib, a proteasome inhibitor with anti-myeloma effects, have been reported. We aimed to evaluate the impact of different bortezomib-containing regimens (BCR) for the treatment of transplant-ineligible MM. All- consecutive patients treated with BCR at our institution from 01/05 to 02/16 were evaluated. With a median of 6 cycles, an overall response rate of 95...
January 10, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28062906/programmed-cell-death-1-pathway-inhibition-in-myeloid-malignancies-implications-for-myeloproliferative-neoplasms
#6
REVIEW
D C Choi, D Tremblay, C Iancu-Rubin, J Mascarenhas
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic diseases that belong to the spectrum of myeloid malignancies (MyMs), which also include myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelogenous leukemia (CML). While hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic approach to many MyMs, the associated morbidity and mortality have necessitated the development of non-HSCT therapeutics for symptom management and disease course modification...
January 6, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28058493/outcome-of-allogeneic-hematopoietic-stem-cell-transplantation-in-adult-patients-with-acute-myeloid-leukemia-harboring-trisomy-8
#7
Takaaki Konuma, Tadakazu Kondo, Takuya Yamashita, Naoyuki Uchida, Takahiro Fukuda, Yukiyasu Ozawa, Kazuteru Ohashi, Hiroyasu Ogawa, Chiaki Kato, Satoshi Takahashi, Heiwa Kanamori, Tetsuya Eto, Chiaki Nakaseko, Akio Kohno, Tatsuo Ichinohe, Yoshiko Atsuta, Akiyoshi Takami, Shingo Yano
Trisomy 8 (+8) is one of the most common cytogenetic abnormalities in adult patients with acute myeloid leukemia (AML). However, the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in adult patients with AML harboring +8 remains unclear. To evaluate, the outcome and prognostic factors in patients with AML harboring +8 as the only chromosomal abnormality or in association with other abnormalities, we retrospectively analyzed the Japanese registration data of 631 adult patients with AML harboring +8 treated with allogeneic HSCT between 1990 and 2013...
January 6, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28058492/severe-hepatitis-b-virus-reactivation-related-to-ibrutinib-monotherapy
#8
LETTER
Yair Herishanu, Helena Katchman, Aaron Polliack
No abstract text is available yet for this article.
January 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28058491/evaluating-the-impact-of-genetic-and-epigenetic-aberrations-on-survival-and-response-in-acute-myeloid-leukemia-patients-receiving-epigenetic-therapy
#9
Jan K Hiller, Claudia Schmoor, Verena I Gaidzik, Charlotte Schmidt-Salzmann, Arzu Yalcin, Mahmoud Abdelkarim, Nadja Blagitko-Dorfs, Konstanze Döhner, Lars Bullinger, Justus Duyster, Michael Lübbert, Björn Hackanson
Treatment with hypomethylating agents such as decitabine, which results in overall response rates of up to 50%, has become standard of care in older patients with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. However, there still exists a lack of prognostic and predictive molecular biomarkers that enable selection of patients who are likely to benefit from epigenetic therapy. Here, we investigated distinct genetic (FLT3-ITD, NPM1, DNMT3A) and epigenetic (estrogen receptor alpha (ERα), C/EBPα, and OLIG2) aberrations in 87 AML patients from the recently published phase II decitabine trial (AML00331) to identify potential biomarkers for patients receiving hypomethylating therapy...
January 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28058490/second-line-azacitidine-for-elderly-or-infirmed-patients-with-acute-myeloid-leukemia-aml-not-eligible-for-allogeneic-hematopoietic-cell-transplantation-a-retrospective-national-multicenter-study
#10
Ron Ram, Moshe Gatt, Drorit Merkel, Ilana Helman, Tsofia Inbar, Arnon Nagler, Irit Avivi, Yishai Ofran
Elderly and infirm patients with acute myeloid leukemia (AML) with either induction refractory or relapse disease may benefit from treatment with azacitidine. We retrospectively reviewed the data from five tertiary centers in Israel, treated between 2009 and 2015. Thirty-four patients (median age 74 years) were identified. Sixty-two percent of the patients had relapsed disease and 38% had refractory disease. Median time of follow-up was 12.1 months. Out of a total of 327 courses, incidence of infectious episodes was 6%...
January 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28058489/rare-myopathy-associated-to-mgus-causing-heart-failure-and-responding-to-chemotherapy
#11
LETTER
Nicolas Belhomme, Adel Maamar, Thomas Le Gallou, Marie-Christine Minot-Myhié, Antoine Larralde, Nicolas Champtiaux, Olivier Benveniste, Sarah Leonard-Louis, Olivier Decaux, Alain Lescoat, Yves Le Tulzo
No abstract text is available yet for this article.
January 5, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28054140/meis1-is-critical-to-the-maintenance-of-human-acute-myeloid-leukemia-cells-independent-of-mll-rearrangements
#12
Jiangying Liu, Ya-Zhen Qin, Shenmiao Yang, Yazhe Wang, Ying-Jun Chang, Ting Zhao, Qian Jiang, Xiao-Jun Huang
Although the outcome of patients with acute myeloid leukemia (AML) has improved by optimized chemotherapy regimens and bone marrow transplantation, leukemia relapse remains one of the most challenging problems during therapy. Sustained existence of AML blasts is a fundamental determinant for the development of leukemia and resistance to therapy. Recent evidences suggest that Meis1 is tightly associated with the self-renewal capacity of normal hematopoietic stem cells. Meis1 was also found to be essential for the development of mixed lineage leukemia (MLL)-rearranged leukemia...
January 4, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28050677/cold-agglutinin-disease-complicated-by-acrocyanosis-and-necrosis
#13
LETTER
Gareth P Gregory, Ann Farrell, Susan Brown
No abstract text is available yet for this article.
January 3, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28050676/nutritional-risk-in-allogeneic-stem-cell-transplantation-rationale-for-a-tailored-nutritional-pathway
#14
Takashi Aoyama, Osamu Imataki, Keita Mori, Kanako Yoshitsugu, Masafumi Fukaya, Ikue Okamura, Terukazu Enami, Raine Tatara, Takashi Ikeda
Hematopoietic stem cell transplantation carries nutrition-related risks. Therefore, nutritional therapy needs to be initiated before transplantation even takes place. We assessed nutritional risk among patients who underwent allogeneic stem cell transplantation. We assessed nutrient supply (calorie supply and protein supply) by chart review. Assessments were made from the pretreatment phase of transplantation to after the end of parenteral nutrition in 51 patients who underwent allogeneic stem cell transplantation at Shizuoka Cancer Center between 2007 and 2012...
January 3, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28039512/efficacy-and-safety-of-autologous-hematopoietic-cell-transplantation-in-elderly-patients-with-multiple-myeloma-a-retrospective-national-multi-site-cohort-study
#15
Yael C Cohen, Tsila Zuckerman, Moshe Yeshurun, Galit Perez, Hila Magen, Israel Henig, Itai Levi, Liat Shargian, Svetlana Trestman, Uri Rouvio, Elizabeth Naparstek, Eti Ganon-Elazar, Irit Avivi, Ron Ram
We aimed to test the efficacy and toxicity of autologous hematopoietic cell transplant (HCT) in Multiple Myeloma (MM) patients aged ≥65 years compared to patients aged 60-64. Two hundred twenty consecutive patients (age ≥65, n = 87) with MM aged 60 and above, who underwent HCT as part of an upfront MM treatment, at four Israeli centers between 2000 and 2014 were included. A melphalan dose of 200 mg/m(2) was more frequent in the 60-64 age group vs. the ≥65 age group (77 vs. 57%, p = 0.002). There were no differences between groups in median day of neutrophil engraftment, incidence of infections, grades 3-4 mucositis, cardiovascular events, or non-relapse mortality at 100 days post HCT (4...
December 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28035434/clinico-biological-characteristics-and-outcome-of-hepatitis-c-virus-positive-patients-with-diffuse-large-b-cell-lymphoma-treated-with-immunochemotherapy
#16
Ivan Dlouhy, Miguel Á Torrente, Sabela Lens, Jordina Rovira, Laura Magnano, Eva Giné, Julio Delgado, Olga Balagué, Antonio Martínez, Elías Campo, Xavier Forns, José M Sánchez-Tapias, Armando López-Guillermo
Diffuse large B cell lymphoma (DLBCL) patients carrying hepatitis C virus (HCV) have higher risk of treatment toxicity and complications. The aim of this study was to assess the impact of HCV in a series of DLBCL patients treated with immunochemotherapy. 321 patients (161 M/160F; median age, 66 years) diagnosed with de novo DLBCL in a single center between 2002 and 2013 were included. Immunodeficiency-related lymphomas were excluded. HCV+ cases were defined by the presence of IgG anti-HCV. Main clinico-biological characteristics and outcome were analyzed according to the viral status...
December 29, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28032185/a-treatment-refractory-cd30-positive-diffuse-large-b-cell-lymphoma-in-the-ileal-neobladder
#17
LETTER
Saeko Ota, Toshiki Iwai, Yuka Kawaji, Takahiro Fujino, Muneo Ohshiro, Yoshiko Hirakawa, Yoshiaki Chinen, Hitoji Uchiyama, Hiroto Kaneko, Junya Kuroda
No abstract text is available yet for this article.
December 28, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28028559/real-world-epidemiology-of-myeloproliferative-neoplasms-a-population-based-study-in-korea-2004-2013
#18
Ja Min Byun, Young Jin Kim, Taemi Youk, John Jeongseok Yang, Jongha Yoo, Tae Sung Park
Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1-9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8-5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5-0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000...
December 27, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28018998/fibrinolysis-in-patients-with-a-mild-to-moderate-bleeding-tendency-of-unknown-cause
#19
Johanna Gebhart, Sylvia Kepa, Stefanie Hofer, Silvia Koder, Alexandra Kaider, Alisa S Wolberg, Helmuth Haslacher, Peter Quehenberger, Ernst Eigenbauer, Simon Panzer, Christine Mannhalter, Ingrid Pabinger
In more than 50% of patients with a mild-to-moderate bleeding tendency, no underlying cause can be identified (bleeding of unknown cause, BUC). Data on parameters of fibrinolysis in BUC are scarce in the literature and reveal discrepant results. It was the aim of this study to investigate increased fibrinolysis as a possible mechanism of BUC. We included 270 patients (227 females, median age 44 years, 25-75(th) percentile 32-58) with BUC and 98 healthy controls (65 females, median age 47 years, 25-75(th)percentile 39-55)...
December 26, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/28013360/blastic-plasmacytoid-dendritic-cell-neoplasm-with-transient-response-to-pralatrexate
#20
LETTER
Christian Arranto, Alexandar Tzankov, Jörg Halter
No abstract text is available yet for this article.
December 24, 2016: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"